Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | GLA | P06280 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | CASP7 | P55210 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16561901 | 1.00 | PTGDR2 (0.65) | PTGDR2KDM4EGLAMEN1CASP1 | |
| Hydrochloric Acid SCHEMBL3020304 | 0.99 | PTGDR2 (0.64) | PTGDR2KDM4EGLAMEN1CASP1 | |
| Hydrochloric Acid SCHEMBL3020302 | 0.99 | PTGDR2 (0.64) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL16559078 | 0.89 | KDM4E (0.67) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL13273561 | 0.89 | KDM4E (0.67) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL4509853 | 0.86 | PTGDR2 (0.77) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL13677407 | 0.85 | PTGDR2 (0.52) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL27989288 | 0.83 | KDM4E (0.59) | PTGDR2KDM4EGLAMEN1CASP1 | |
| SCHEMBL2493010 | 0.83 | PTGDR2 (0.47) | PTGDR2KDM4EGLAMEN1CASP1 | |
| Bromide SCHEMBL2430564 | 0.83 | KDM4E (0.58) | PTGDR2KDM4EGLAMEN1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| WO-2021066136-A1 | THERAPEUTIC AGENT FOR MUSCULAR DYSTROPHY | 国立大学法人東京大学 | 2021-04-08 | — | — | WO | disclosed |
| US-20200123512-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-04-23 | — | — | US | disclosed |
| US-10544402-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2828385-B1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | CODEXIS INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170283781-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-10-05 | — | — | US | disclosed |
| US-9708588-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160289649-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-10-06 | — | — | US | disclosed |
| EP-2697223-B1 | 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-A]INDOL ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9388395-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| CN-101500996-A | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-05 | — | — | CN | disclosed |
| CN-101500996-A | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-05 | — | — | CN | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | PTGDR2 4/4885KDM4E 3845/4885GLA 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.